한국유니온제약, 상폐 효력정지 가처분 신청

The delisting decision for Korea Union Pharmaceutical signals heightened regulatory scrutiny and financial instability within the South Korean pharmaceutical sector. This legal challenge against the KOSDAQ Market Committee's decision is a critical event that highlights the risks of investment in the bio-healthcare industry and the importance of maintaining listing eligibility.